VivoSeq
Oncology

Primitive Neuroectodermal Tumor

31

Pipeline Programs↗

0

Active Trials↗

14

Companies Involved↗

Primitive Neuroectodermal Tumor is a moderately active landscape with 31 programs across 14 companies. The most active players are Akero Therapeutics, Gynecologic Oncology Group, Kura Oncology, Inc.. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

91/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 1G

Gynecologic Oncology Group

3 programs

Phase 2K

Kura Oncology, Inc.

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

29 of 32 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody26%Protein / enzyme13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed20 · 87%
Terminated2 · 9%
Unknown status1 · 4%

Clinical Trials

Trial Activity

23 trials

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Completed·National Cancer Institute (NCI)·Phase 2·NCT01217437·108 enrolled
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
Completed·National Cancer Institute (NCI)·Phase 2·NCT00002643·130 enrolled
Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00303810·567 enrolled
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00003211·94 enrolled
Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Completed·PPediatric Brain Tumor Consortium·Phase 2·NCT00047177·43 enrolled
Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
Completed·UUniversity of Colorado, Denver·Phase 2·NCT01542736·8 enrolled
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001209·120 enrolled
Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS
Completed·SSociete Internationale d'Oncologie Pediatrique·Phase 3·NCT00003859·230 enrolled
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
Completed·—·Phase 2·NCT00006258
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma
Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003081·16 enrolled
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00070525·90 enrolled
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Completed·UUniversity of Florida·Phase 2·NCT01326104·26 enrolled
Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002463·4 enrolled
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
Completed·National Cancer Institute (NCI)·Phase 1·NCT00609141·34 enrolled
Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Completed·—·Phase 2·NCT00003460·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)